ESGCT 2026 Preview: Gene and Cell Therapy Trends
ESGCT 2026 at a glance ESGCT 2026 will spotlight emerging cell and gene therapy…
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic partnership for late-phase AAV manufacturing
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic…

